Featured Posters & Presentations
Lyfgenia
Updated results from the HGB-206 study in patients with severe sickle cell disease treated under a revised protocol with LentiGlobin gene therapy using plerixafor-mobilized hematopoietic stem cells.
Authors: Kanter JA.
Zynteglo
Safety and efficacy of LentiGlobin gene therapy in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes in the phase 3 Northstar-2 study.
Authors: Locatelli F.
Zynteglo
Results from the phase 3 Northstar-3 study evaluating the safety and efficacy of LentiGlobin gene therapy in patients with transfusion-dependent β-thalassemia and a β0 or IVS-I-110 mutation at both alleles of the HBB gene.
Authors: Kulozik AE.
Zynteglo
Clinical outcomes of LentiGlobin gene therapy for transfusion-dependent β-thalassemia (TDT) following completion of the Northstar (HGB-204) study.
Authors: Walters MC.